Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers

Immunobiology

Volumn 221, Issue 5, 2016, Pages 604-617

  Koeck, Stefan ^a,c   Zwierzina, Marit ^a   Huber, Julia M ^a,c   Bitsche, Mario ^a   Lorenz, Edith ^a,c   Gamerith, Gabriele ^a,c   Dudas, Jozsef ^a   Kelm, Jens M ^b   Zwierzina, Heinz ^a,c   Amann, Arno ^a,c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b InSphero AG   (Switzerland)

^c TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

3D; Biomarker; Cancer; Co culture; Immune cells; Infiltration; Subpopulation

Indexed keywords

BIOLOGICAL MARKER; CD28 ANTIGEN; CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 2; MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER MICROTISSUE; CELL AGGREGATION; CELL INTERACTION; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG SCREENING; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; LUNG CANCER CELL LINE; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; NON SMALL CELL LUNG CANCER; ONCOLOGICAL PARAMETERS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; THREE DIMENSIONAL CELL CULTURE SYSTEM; CELL SURVIVAL; COCULTURE; CYTOTOXICITY; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; METABOLISM; MONOCYTE; MULTICELLULAR SPHEROID; NEOPLASM; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANTIGENS, SURFACE; BIOMARKERS; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE SUBSETS; LYMPHOCYTES, TUMOR-INFILTRATING; MONOCYTES; NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84960517008     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2015.12.010     Document Type: Article

References (30)

1. Allinen M., Beroukhim R., Cai L., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6(1):17-32. PubMedPMID:15261139. 10.1016/j.ccr.2004.06.010.
2. Amann A., Zwierzina M., Gamerith G., et al. Development of an innovative 3D cell culture system to study tumour-stroma interactions in non-small cell lung cancer cells. PLoS One 2014, 9(3):e92511. PubMed PMID: 24663399; PubMed Central PMCID: PMC3963897. 10.1371/journal.pone.0092511.
3. Burkholder B., Huang R.Y., Burgess R., et al. Tumor-induced perturbations of cytokines and immune cell networks. Biochim. Biophys. Acta 2014, 1845(April (2)):182-201. 10.1016/j.bbcan.2014.01.004.
4. Chouaib S., Kieda C., Benlalam H., et al. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit. Rev. Immunol. 2010, 30(6):529-545.
5. Feder-Mengus C., Ghosh S., Reschner A., et al. New dimensions in tumor immunology: what does 3D culture reveal?. Trends Mol. Med. 2008, 14(8):333-340. PubMedPMID:18614399. 10.1016/j.molmed.2008.06.001.
6. Finn O.J. Cancer immunology. N. Engl. J. Med. 2008, 358(25):2704-2715. PubMedPMID:18565863. 10.1056/NEJMra072739.
7. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147(5):992-1009. PubMedPMID:22118458. 10.1016/j.cell.2011.11.016.
8. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14(October (10)):1014-1022. 10.1038/ni.2703.
9. Garcia-Lora A., Algarra I., Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 2003, 195(June (3)):346-355.
10. Ghosh S., Rosenthal R., Zajac P., et al. Culture of melanoma cells in 3-dimensional architectures results in impaired immunorecognition by cytotoxic T lymphocytes specific for Melan-A/MART-1 tumor-associated antigen. Ann. Surg. 2005, 242(6):851-857. discussion 8. PubMed PMID: 16327495; PubMed Central PMCID: PMC1409875.
11. Grivennikov S.I., Greten F.R., Karin M. Immunity, Inflammation, and Cancer. Cell 2010, 140(Marchy 19 (6)):883-899. 10.1016/j.cell.2010.01.025.
12. Harma V., Virtanen J., Makela R., et al. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010, 5(5):e10431. PubMed PMID: 20454659; PubMed Central PMCID: PMC2862707. 10.1371/journal.pone.0010431.
13. Hayashida T., Jinno H., Kitagawa Y., et al. Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J. Oncol. 2011, 591427. PubMed PMID: 21253528;PubMed Central PMCID: PMC3021841. 10.1155/2011/591427.
14. Hickman J.A., Graeser R., de Hoogt R., et al. Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol. J. 2014, 9(9):1115-1128. PubMedPMID:25174503. 10.1002/biot.201300492.
15. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363(8):711-723. PubMed PMID: 20525992;PubMed Central PMCID: PMC3549297. 10.1056/NEJMoa1003466.
16. Jewett A., Nakamura H., Wang M., et al. Dedifferentiation of epithelial tumors enhances cytotoxicity survival and expansion of allogeneic CD8+ T cells and natural killer cells. J. Carcinog. Mutagen. 2012, S1:007.
17. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005, 352(8):786-792. PubMedPMID:15728811. 10.1056/NEJMoa044238.
18. Kraman M., Bambrough P.J., Arnold J.N., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830. 10.1126/science.1195300.
19. Ma, P.C., Personalized targeted therapy in advanced non-small cell lung cancer Cleve Clin J Med. 2012. 79 Electronic Suppl 1:e 2012 S56-60 10.3949/ccjm.79.s2.12. PubMed PMID: 22614968.
20. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172(5):2731-2738. PubMed PMID: 14978070.
21. Mlecnik B., Tosolini M., Kirilovsky A., et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 2011, 29(6):610-618. PubMedPMID:21245428. 10.1200/JCO.2010.30.5425.
22. Pages F., Kirilovsky A., Mlecnik B., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 2009, 27(35):5944-5951. PubMedPMID:19858404. 10.1200/JCO.2008.19.6147.
23. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, (April 2012):252-264. 10.1038/nrc3239.
24. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353(2):123-132. PubMedPMID:16014882. 10.1056/NEJMoa050753.
25. Srivastava R.M., Lee S.C., Andrade Filho P.A., et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin. Cancer Res. 2013, 19(7):1858-1872. PubMed PMID: 23444227;PubMed Central PMCID: PMC3640274. 10.1158/1078-0432.CCR-12-2426.
26. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin. Cancer Biol. 2000, 10(6):415-433. PubMedPMID:11170864. 10.1006/scbi.2000.0379.
27. Robert C., Long G.V., Brady B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372(4):320-330. PubMedPMID:25399552. 10.1056/NEJMoa1412082.
28. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12(4):237-251. PubMed PMID: 22437869; PubMed Central PMCID: PMC3967236. 10.1038/nrc3237.
29. Weiner L.M., Dhodapkar M.V., Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373(9668):1033-1040. PubMed PMID:19304016; PubMed Central PMCID: PMC2677705. 10.1016/S0140-6736(09)60251-8.
30. Wolchok J.D., Kluger H., Callahan M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369(2):122-133. PubMed PMID:23724867. 10.1056/NEJMoa1302369.